India’s Pharma Exports Surge Over 9% In 2025

India’s pharmaceutical industry has once again demonstrated its global strength, recording a 9% jump in exports during 2025. Commerce Secretary Sunil Barthwal emphasized that Indian pharma products are now recognized for their quality, affordability, and reliability across international markets. The growth comes amid rising global healthcare needs and India’s expanding footprint in generics, vaccines, and specialty drugs.  

Key highlights from the announcement include  

• Pharma exports grew over 9% in 2025, driven by strong demand in the US, Europe, Africa, and Latin America.  
• India continues to be the largest supplier of generic medicines globally, accounting for 20% of worldwide exports.  
• The country’s vaccine exports, particularly for COVID-19 and other infectious diseases, remain a major contributor.  
• Commerce Secretary noted that Indian pharma companies are increasingly investing in R&D and innovation.  
• Government support through Production Linked Incentive (PLI) schemes has boosted manufacturing capacity and competitiveness.  
• India’s pharma exports are expected to cross $28 billion in 2025, up from $25.6 billion last year.  
• The industry is also expanding into biosimilars and complex generics, strengthening its global portfolio.  

Experts highlight that India’s pharmaceutical sector has become a critical pillar of global healthcare, ensuring affordable access to essential medicines. The recognition of Indian products in regulated markets such as the US and EU underscores the industry’s adherence to stringent quality standards.  

Looking ahead, India’s pharma industry is expected to maintain strong growth momentum, supported by innovation, government incentives, and expanding global partnerships. The sector’s resilience and adaptability continue to reinforce its reputation as the “Pharmacy of the World.”  

Sources: Economic Times, Business Standard, Mint, Financial Express, Pharmabiz